IGM Biosciences stock has experienced a significant decline, indicating an overall bearish sentiment in the market. The company's high expenses and poor financial management have devalued the company.

The iShares Expanded Tech Sector ETF (NYSEARCA:IGM) is a comprehensive ETF that gives investors exposure to the full spectrum of the North American tech sector, as it includes key tech-related stocks ...

I maintain my buy rating on iShares Expanded Tech Sector ETF, expecting strong returns as tech stocks benefit from robust earnings, AI demand, and favorable macro conditions. IGM’s diversified ...

4 analysts have expressed a variety of opinions on IGM Biosciences (NASDAQ:IGMS) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

IGM Financial Inc (TSX:IGM) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue is $0.81 billion, and the earnings are expected to come in at $1.02 per ...

Natural IgM, a pentameric, polyreactive antibody, is mainly secreted by peritoneal B1 B cells and recognizes and binds self antigens such as phospholipids. The unique structure of natural IgM allows ...

Mountain View, California-based IGM Biosciences, Inc. proposes to offer 10.938 million shares in an IPO at an estimated price range of $15-$17 per share, according to a S-1/A filing. The offering has ...

IGM's combination of the in-house investment management groups from Mackenzie and Investors Group into a single shop (housed under the Mackenzie Investments brand) has enhanced the scale of the firm's ...

Readers hoping to buy IGM Financial Inc. (TSE:IGM) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before ...

Forbes contributors publish independent expert analyses and insights. We provide aggregated data on dividend stocks. The report stated, ''Dividend investors approaching investing from a value ...